GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — have transformed obesity medicine. Clinical trials demonstrate average weight reductions of 15–22% of body weight over 68–72 weeks, representing outcomes previously achievable only through bariatric surgery. But as millions of people begin these medications, an important clinical concern has emerged: a meaningful portion of the weight lost is not fat — it is skeletal muscle.

This is not a reason to avoid GLP-1 medications. The benefits — cardiovascular, metabolic, and quality-of-life — remain substantial and well-documented. But it is a reason to be strategic about how you use these medications. Understanding the muscle loss problem, why it matters, and how to minimize it is essential for anyone beginning or currently on a GLP-1 regimen.

Why GLP-1 Drugs Cause Muscle Loss

GLP-1 receptor agonists suppress appetite — often dramatically. This is their primary mechanism for producing weight loss: people consume significantly fewer calories, creating a sustained caloric deficit that drives fat mobilization and weight reduction. The challenge is that prolonged caloric restriction — regardless of the mechanism — creates conditions that promote lean tissue catabolism alongside fat loss.

When caloric intake drops steeply, the body enters a state of energy deficit. While adipose tissue is the preferred fuel source, the body cannot rely exclusively on fat during periods of very low caloric intake or rapid weight loss. Muscle protein is also catabolized — broken down into amino acids that can be used for gluconeogenesis (glucose production) and energy. This is a survival mechanism, but it works against the goal of achieving a healthy body composition.

Several additional factors compound the muscle loss risk on GLP-1 therapy:

How Much Muscle Is Actually Lost?

The data on this question is sobering. Multiple body composition studies using DEXA (dual-energy X-ray absorptiometry) scanning have tracked the composition of weight lost during GLP-1 therapy:

To put this in concrete terms: a person who loses 50 pounds on semaglutide might lose 30–38 pounds of fat and 12–20 pounds of muscle. That muscle loss has real consequences — both now and in the future.

Why Muscle Loss Matters: Long-Term Metabolic Consequences

Skeletal muscle is the largest metabolically active tissue in the human body. It is responsible for the majority of glucose uptake in the post-meal period, and it is a primary determinant of resting metabolic rate (RMR) — the number of calories your body burns at rest. Losing significant muscle mass has cascading effects:

Reduced Resting Metabolic Rate

Muscle tissue burns approximately 6–10 calories per pound per day at rest, compared to roughly 2 calories per pound for fat. Losing 15 pounds of muscle reduces resting metabolic rate by an estimated 90–150 calories per day — meaning the body burns fewer calories even at rest. This metabolic adaptation makes weight regain more likely and maintenance harder when the medication is discontinued or reduced.

Increased Insulin Resistance Risk

Muscle is the primary site of insulin-stimulated glucose disposal. Less muscle means reduced capacity to clear blood glucose effectively. This is particularly concerning for people using GLP-1 medications partly to improve insulin sensitivity — if muscle mass declines significantly, some of the metabolic benefit may be offset.

Functional Decline and Sarcopenia Risk

Muscle mass is the primary predictor of physical function, strength, and independence — particularly in aging adults. Losing 15–20 pounds of muscle at age 55 or 65 can meaningfully impair mobility, increase fall risk, and accelerate the progression toward sarcopenia (age-related muscle loss). For older adults on GLP-1 therapy, muscle preservation is especially critical.

Worse Body Composition After Regain

If weight is regained after stopping GLP-1 therapy — which occurs in the majority of patients who discontinue — the regained weight is predominantly fat. Net result: the patient ends up with the same or higher body weight as before treatment, but with worse body composition — less muscle and more fat — than when they started.

Strategy 1: Optimize Protein Intake

Adequate protein intake is the single most important dietary intervention for preserving lean mass during weight loss. Protein provides amino acids needed for muscle protein synthesis, and high protein intake creates an anabolic signal that partially counteracts the catabolic pressures of caloric restriction.

Current evidence-based recommendations for protein intake during active weight loss:

For a 200-pound (91 kg) man, this translates to approximately 110–145 grams of protein per day at the lower range, or up to 182–218 grams at the higher range during aggressive weight loss phases.

Because GLP-1 medications often reduce the palatability of protein-dense foods, intentional meal planning and supplementation (whey protein shakes, protein-fortified foods) may be necessary to hit these targets despite appetite suppression.

Strategy 2: Resistance Training Is Non-Negotiable

Exercise — specifically resistance training — is the most powerful stimulus for maintaining muscle mass during caloric restriction. Strength training signals muscle protein synthesis pathways (primarily through mTOR activation) and counteracts the catabolic drive of energy deficit.

Studies of resistance training during caloric deficit consistently show that individuals who strength train lose significantly more fat and significantly less muscle than those who diet without exercise. A 2021 meta-analysis in the British Journal of Sports Medicine confirmed that resistance training during caloric restriction may nearly eliminate lean mass loss compared to diet-only interventions.

Practical recommendations for resistance training on GLP-1 therapy:

Strategy 3: Consider Creatine Supplementation

Creatine monohydrate is among the most studied and evidence-supported supplements in exercise science. Its primary benefits include increased phosphocreatine stores in muscle (supporting ATP regeneration during high-intensity effort), increased intramuscular water content (which may reduce protein catabolism), and emerging evidence for direct anti-catabolic effects during caloric deficit.

During GLP-1 therapy, creatine supplementation may help buffer some of the lean mass loss — particularly for individuals engaged in resistance training. Standard dosing is 3–5 grams per day. It is well tolerated, inexpensive, and has an excellent long-term safety profile. Note that creatine loading increases intramuscular water content, which will temporarily elevate the number on the scale — this represents water in muscle, not fat, and is not a concern.

Strategy 4: Monitor With Body Composition Testing

Standard scales measure total body weight — but give no information about how much of that weight is fat versus muscle. A person who loses 20 pounds but 8 of those pounds are muscle has a very different outcome than someone who loses 20 pounds of nearly pure fat.

Body composition testing — via DEXA scan, bioelectrical impedance analysis (BIA), or hydrostatic weighing — provides a clearer picture of fat mass versus lean mass changes over time. Tracking both during GLP-1 therapy allows physician and patient to assess whether the weight loss trajectory is preserving lean mass adequately, and to adjust interventions if muscle loss is occurring at a concerning rate.

Physician monitoring also allows for proactive lab assessment — checking markers like albumin, prealbumin, and complete metabolic panel — to catch any signs of excessive protein catabolism or nutritional deficiency.

The Role of Peptides in Muscle Preservation

Some patients on GLP-1 therapy explore adjunctive interventions from the peptide category to support lean mass preservation. Growth hormone-stimulating peptides such as CJC-1295 and Ipamorelin may promote anabolic signaling and help offset some catabolic pressure of caloric restriction, though this approach requires physician oversight and is considered off-label. Explore our peptide program to learn more about these options.

Working With a Physician on GLP-1 Therapy

The muscle loss issue underscores why GLP-1 therapy should not be self-managed. A physician-supervised approach allows for regular assessment of body composition changes, dose optimization to balance weight loss efficacy with tolerable side effects (including appetite suppression intensity), protein intake guidance based on your specific body weight and activity level, and integration of exercise programming recommendations.

Truventa's weight loss program pairs patients with licensed physicians who monitor progress throughout therapy — not just at initiation. Our comprehensive approach includes nutritional guidance specifically designed to address lean mass preservation. For more detail on how semaglutide-based weight loss works, see our complete semaglutide weight loss guide.

The goal of GLP-1 therapy should not simply be to reduce the number on the scale — it should be to improve body composition, metabolic health, and long-term physical function. With the right supportive strategies, this is achievable.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making changes to your weight loss or exercise regimen.